Overall, we preliminarily surmise that IL-33 may orchestrate an immune-activated TME by mediating a positive feedback loop between T cells and CRC cells, which cooperates with 5-FU to inhibit tumor progression. This evidence concerns the gene IL33 and colorectal carcinoma.